<DOC>
	<DOCNO>NCT00939770</DOCNO>
	<brief_summary>RATIONALE : Crizotinib may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I/II trial study side effect best dose crizotinib see well work treat young patient relapsed refractory solid tumor anaplastic large cell lymphoma .</brief_summary>
	<brief_title>Crizotinib Treating Young Patients With Relapsed Refractory Solid Tumors Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate maximum-tolerated dose recommend phase II dose crizotinib administer orally twice daily child relapse refractory solid tumor anaplastic large cell lymphoma ( ALCL ) . - To define describe toxicity drug administer schedule . - To characterize pharmacokinetics drug patient . Secondary - To preliminarily define antitumor activity drug within confines phase I study . - To obtain initial phase II data antitumor activity drug child relapse refractory neuroblastoma ALCL . - To preliminarily examine relationship response treatment anaplastic lymphoma kinase gene status ( e.g. , presence mutation , duplication , amplification , and/or translocation ) child relapse refractory neuroblastoma ALCL . - To preliminarily examine relationship minimal residual disease status clinical response treatment child ALCL . OUTLINE : This multicenter , phase I dose-escalation study follow phase II study . Patients receive oral crizotinib twice daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Plasma whole blood sample collect pharmacokinetic pharmacogenomic analysis . Tumor tissue ( patient neuroblastoma ) bone marrow and/or peripheral blood ( patient anaplastic large cell lymphoma ) sample collect correlative laboratory study . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* malignancy original diagnosis relapse , include follow : Solid tumor ( phase I ) CNS tumor ( phase I ) Neurologic deficit must relatively stable ≥ 1 week study enrollment Anaplastic large cell lymphoma ( ALCL ) ( phase I II ) No primary cutaneous ALCL Confirmed anaplastic lymphoma kinase ( ALK ) fusion protein , ALK mutation , ALK amplification ( define &gt; 4fold increase ALK signal number compare reference signal number chromosome 2q arm ) ( phase I ) Neuroblastoma ( phase I II ) NOTE : *Histologic confirmation require patient diffuse intrinsic brain stem tumor , optic pathway tumor , pineal region tumor elevation serum CSF tumor marker ( e.g. , alphafetoprotein betaHCG ) . Relapsed refractory disease Measurable and/or evaluable disease Patients neuroblastoma must measurable tumor MRI , CT scan , xray obtain within past 2 week and/or evaluable tumor MIBG scan and/or bone marrow involvement tumor cell see routine morphology Patients ALCL enrol phase II portion trial must measurable disease No known curative therapy therapy proven prolong survival acceptable quality life exist PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( patient &gt; 16 year age ) Lansky PS 50100 % ( patient ≤ 16 year age ) Patients wheelchair unable walk due paralysis consider ambulatory purpose assess PS ANC ≥ 1,000/mm^3 ( ≥ 750/mm^3 patient metastatic bone marrow disease ) Platelet count ≥ 75,000/mm^3 ( transfusion independent , defined platelet transfusion within past 7 day ) patient without bone marrow involvement OR ≥ 25,000/mm^3 ( platelet transfusion allow ) patient metastatic bone marrow disease Hemoglobin ≥ 8.0 g/dL ( RBC transfusion allow ) Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age/gender follow : ≤ 0.6 mg/dL ( patient 1 year age ) ≤ 0.8 mg/dL ( patient 2 5 year age ) ≤ 1.0 mg/dL ( patient 6 9 year age ) ≤ 1.2 mg/dL ( patient 10 12 year age ) ≤ 1.4 mg/dL ( female patient ≥ 13 year age ) ≤ 1.5 mg/dL ( male patient 13 15 year age ) ≤ 1.7 mg/dL ( male patient ≥ 16 year age ) Bilirubin ( sum conjugate unconjugated ) ≤ 1.5 time upper limit normal age SGPT ≤ 110 U/L Serum albumin ≥ 2 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Body surface area ≥ 0.4 mm² ( patient enrol dose level 0 1 ) Able swallow capsule liquid suspension/solution Able comply safety monitoring requirement study , opinion investigator No uncontrolled infection No evidence active graft v host disease Not refractory red cell platelet transfusion ( patient metastatic bone marrow disease ) PRIOR CONCURRENT THERAPY : Recovered prior chemotherapy , immunotherapy , radiotherapy No prior crizotinib At least 6 month since prior totalbody radiotherapy ( TBI ) , craniospinal radiotherapy , radiotherapy ≥ 50 % pelvis At least 3 month since prior bone marrow stem cell transplant ( without TBI ) ( ≥ 6 week patient neuroblastoma patient confirm ALK fusion protein , ALK mutation , ALK amplification ) No evidence active graftvshost disease At least 6 week since prior therapeutic dos MIBG At least 6 week since prior substantial bone marrow radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) patient solid tumor At least 14 day since prior cytotoxic therapy patient ALCL relapse receive cytotoxic therapy Patients lymphoma relapse standard maintenance therapy eligible time relapse Cytoreduction hydroxyurea may initiate continue 24 hour start study treatment At least 7 day since prior growth factor therapy At least 7 day since prior biological agent At least 7 day 3 halflives ( whichever longer ) since prior monoclonal antibody More 12 day since prior concurrent potent CYP3A4 inducer include , limited carbamazepine , phenobarbital , phenytoin , rifabutin , rifampin , tipranavir , ritonavir , St. John wort More 7 day since prior concurrent potent CYP3A4 inhibitor include , limited ketoconazole , itraconazole , miconazole , clarithromycin , erythromycin , ritonavir , indinavir , nelfinavir , saquinavir , amprenavir , delavirdine , nefazodone , diltiazem , verapamil , grapefruit juice No concurrent medication know metabolized CYP3A4 narrow therapeutic index , include pimozide , aripiprazole , triazolam , ergotamine , halofantrine No concurrent anticancer therapy ( include chemotherapy , radiotherapy , immunotherapy , biologic therapy ) , except hydroxyurea patient ALCL decadron patient CNS tumors No concurrent investigational drug Concurrent corticosteroid CNS tumor allow provide dose stable decrease past 7 day</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood anaplastic astrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
	<keyword>recurrent childhood fibrillary astrocytoma</keyword>
	<keyword>recurrent childhood gemistocytic astrocytoma</keyword>
	<keyword>recurrent childhood giant cell glioblastoma</keyword>
	<keyword>recurrent childhood glioblastoma</keyword>
	<keyword>recurrent childhood gliomatosis cerebri</keyword>
	<keyword>recurrent childhood gliosarcoma</keyword>
	<keyword>recurrent childhood oligoastrocytoma</keyword>
	<keyword>recurrent childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood pilocytic astrocytoma</keyword>
	<keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
	<keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
	<keyword>recurrent childhood protoplasmic astrocytoma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood ependymoblastoma</keyword>
	<keyword>childhood medulloepithelioma</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood spinal cord neoplasm</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood high-grade cerebellar astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebellar astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
</DOC>